This test is most useful if any of these apply to you.
Ragweed pollen is a common cause of late-summer and fall hay fever in North America. Giant ragweed IgE measures antibodies that recognize pollen from giant ragweed (Ambrosia trifida). It can help explain seasonal symptoms, but a positive result needs to fit your exposure and symptom history.
Giant ragweed and common ragweed share many pollen proteins, though their allergens aren't identical. Antibodies can recognize both species, which makes the results harder to separate than the plant names suggest. Testing supports an allergy diagnosis; it doesn't identify the cause of every positive result by itself.
IgE stands for immunoglobulin E. These antibodies participate in allergic reactions by attaching to mast cells and basophils. Those immune cells can release histamine and other inflammatory chemicals when an allergen binds to the attached antibodies.
This test measures IgE in serum that binds to an extract of giant ragweed pollen. The laboratory uses a fluorescence enzyme immunoassay. A fluorescent signal measures how much antibody has bound to the extract. The result describes circulating antibodies, without directly measuring the reaction in your nose, eyes or lungs.
Detectable allergen-specific IgE provides evidence of sensitization. Sensitization means your immune system recognizes an allergen, and it can occur without symptoms. Your immune system can continue producing IgE between exposures, so a positive result outside pollen season can still be relevant.
Most ragweed research concerns common ragweed (Ambrosia artemisiifolia), also called short ragweed. Amb a 1 is a major allergenic protein in its pollen. In one study, antibodies to Amb a 1 accounted for more than half of the serum common-ragweed IgE in most participants. Giant-ragweed extract contains a different mixture of related proteins, so findings about common-ragweed extract or Amb a 1 need to be interpreted separately.
The distinction can matter clinically. In an Italian study, 6 of 41 people with ragweed allergy reacted strongly to short ragweed on skin testing but were negative to giant ragweed. Laboratory experiments using their serum also found that giant-ragweed extract did not fully block antibody binding to some short-ragweed proteins. These were skin tests and experimental antibody-binding studies, not a validation of this serum test's accuracy.
Results for the two species can therefore differ, but two positive results don't necessarily establish two separate allergies. Shared proteins can account for both. Which species grows locally and when your symptoms occur remain part of the interpretation.
Ragweed allergy commonly causes sneezing, a runny or blocked nose, and itchy or watery eyes. In a selected group of 150 adults with common-ragweed allergy, all reported nasal symptoms and most reported eye symptoms. About three fifths also reported asthma-like symptoms, and about a quarter reported skin symptoms. These figures describe that study population; they aren't probabilities attached to a positive giant-ragweed result.
Higher specific IgE sometimes accompanies worse symptoms, but the relationship varies. A study measured serum IgE to birch, dust mite and pellitory allergens in 8,098 people and assessed symptom severity in a subgroup of 531 people with a single allergy. Several antibody responses were lower at older ages, and antibody levels correlated with symptom severity in the subgroup. Giant-ragweed IgE was not measured.
An early study of serum short-ragweed IgE found a relationship with symptom scores in highly sensitive untreated people, but not in those who were less sensitive. A giant-ragweed IgE concentration cannot reliably forecast how difficult your next pollen season will be.
Ragweed pollen can trigger asthma symptoms in people who are allergic to it. Research on individual common-ragweed proteins suggests that the pattern of antibody recognition may matter. In a study of 150 ragweed-allergic adults, serum antibodies to Amb a 11 were associated with about 4.7 times the odds of more severe asthma or asthma-like symptoms. That finding came from a research assay for one common-ragweed protein. It does not establish giant-ragweed extract IgE as an asthma-severity test.
Broader sensitization studies also find an association with airway disease. Among about 15,000 Danish adults followed for a median of 11.3 years, sensitization to common airborne allergens was associated with more than twice the rate of subsequent registry-recorded asthma events. The tested allergens did not include ragweed. That study supports an association between allergic sensitization and asthma, without providing a risk estimate for this result.
Cross-reactivity occurs when the same antibodies recognize similar structures in different allergens. Pollen extracts contain shared proteins and sugar structures that can produce this pattern. Profilins are one family of proteins shared by many plants. Giant ragweed contains a profilin, and common-ragweed studies have shown extensive antibody cross-reactivity with profilins from birch, grass and mugwort.
In a German study of 74 people with seasonal nose and eye allergy, 55 had serum IgE to common-ragweed extract, while only six had IgE to Amb a 1. The investigators attributed much of the extract positivity to cross-reactivity. Those findings concern common ragweed and a particular local population; they don't mean most positive giant-ragweed results are irrelevant.
Sugar structures can also affect extract testing. In a southern Chinese study, blocking antibodies to shared sugar structures made 22 of 27 common-ragweed positives become negative in a selected subgroup with those antibodies. This was an experiment using a different assay, not an estimate of the false-positive rate of this giant-ragweed test.
Ragweed and mugwort pollen seasons overlap in many regions. In a Beijing study, about 55% of 673 people positive to common ragweed or mugwort were positive to both. Studies have found both separate sensitizations and cross-reactivity, depending on the population and the proteins examined.
Component tests measure IgE against individual allergen proteins. Amb a 1 testing can help assess common-ragweed sensitization, but Amb a 1 itself can cross-react with mugwort proteins. A negative Amb a 1 result also leaves open sensitivity to other ragweed proteins, including those in giant ragweed.
An older study of 100 people found good agreement between giant-ragweed serum IgE and serial skin testing using two laboratory platforms. A separate study of 85 people with allergic rhinitis found that giant-ragweed serum IgE identified only half of the cases defined by symptoms together with positive skin testing. Performance depends on the population, the assay and what it is compared with.
A positive result supports sensitization, but shared pollen structures can make it difficult to identify the original trigger. A negative result reduces the evidence for circulating sensitization without fully excluding a clinically relevant allergy.
Specific IgE is a changing immune measurement, but a lower number does not reliably establish that your allergy has improved. In ragweed immunotherapy studies, changes in antibody levels did not consistently predict clinical benefit. Symptom burden and the amount of medication you need provide more useful measures of treatment response.
Evidence-backed interventions that affect your Giant Ragweed IgE level
Giant Ragweed IgE is best interpreted alongside these tests.
Giant Ragweed IgE is included in these pre-built panels.
See exactly which airborne triggers your body reacts to, so your sneezing, congestion, and wheezing finally have names.
See a wide map of the foods and airborne triggers your immune system reacts to, so you can stop guessing what sets off your symptoms.
80 biomarkers